Literature DB >> 16113050

Pulmonary vascular iNOS induction participates in the onset of chronic hypoxic pulmonary hypertension.

Václav Hampl1, Jana Bíbová, Alena Banasová, Jirí Uhlík, Dana Miková, Olga Hnilicková, Vera Lachmanová, Jan Herget.   

Abstract

Pathogenesis of hypoxic pulmonary hypertension is initiated by oxidative injury to the pulmonary vascular wall. Because nitric oxide (NO) can contribute to oxidative stress and because the inducible isoform of NO synthase (iNOS) is often upregulated in association with tissue injury, we hypothesized that iNOS-derived NO participates in the pulmonary vascular wall injury at the onset of hypoxic pulmonary hypertension. An effective and selective dose of an iNOS inhibitor, L-N6-(1-iminoethyl)lysine (L-NIL), for chronic peroral treatment was first determined (8 mg/l in drinking water) by measuring exhaled NO concentration and systemic arterial pressure after LPS injection under ketamine+xylazine anesthesia. A separate batch of rats was then exposed to hypoxia (10% O2) and given L-NIL or a nonselective inhibitor of all NO synthases, N(G)-nitro-L-arginine methyl ester (L-NAME, 500 mg/l), in drinking water. Both inhibitors, applied just before and during 1-wk hypoxia, equally reduced pulmonary arterial pressure (PAP) measured under ketamine+xylazine anesthesia. If hypoxia continued for 2 more wk after L-NIL treatment was discontinued, PAP was still lower than in untreated hypoxic controls. Immunostaining of lung vessels showed negligible iNOS presence in control rats, striking iNOS expression after 4 days of hypoxia, and return of iNOS immunostaining toward normally low levels after 20 days of hypoxia. Lung NO production, measured as NO concentration in exhaled air, was markedly elevated as early as on the first day of hypoxia. We conclude that transient iNOS induction in the pulmonary vascular wall at the beginning of chronic hypoxia participates in the pathogenesis of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113050     DOI: 10.1152/ajplung.00023.2005

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  17 in total

1.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 2.  Molecular Basis of Nitrative Stress in the Pathogenesis of Pulmonary Hypertension.

Authors:  Colin E Evans; You-Yang Zhao
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

3.  A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion.

Authors:  Thenappan Thenappan; Ankush Goel; Glenn Marsboom; Yong-Hu Fang; Peter T Toth; Hannah J Zhang; Hidemi Kajimoto; Zhigang Hong; Jonathan Paul; Christian Wietholt; Jennifer Pogoriler; Lin Piao; Jalees Rehman; Stephen L Archer
Journal:  Am J Respir Crit Care Med       Date:  2010-12-10       Impact factor: 21.405

4.  Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells.

Authors:  Bojana B Beleslin-Čokić; Vladan P Cokić; Li Wang; Barbora Piknova; Ruifeng Teng; Alan N Schechter; Constance T Noguchi
Journal:  Cytokine       Date:  2011-02-15       Impact factor: 3.861

5.  Inducible NOS inhibitor 1400W reduces hypoxia/re-oxygenation injury in rat lung.

Authors:  Alma Rus; Lourdes Castro; Maria Luisa Del Moral; Angeles Peinado
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

6.  Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.

Authors:  Vincent G DeMarco; Javad Habibi; Adam T Whaley-Connell; Rebecca I Schneider; James R Sowers; Bradley T Andresen; Alex A Gutweiler; Lixin Ma; Megan S Johnson; Carlos M Ferrario; Kevin C Dellsperger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-24       Impact factor: 4.733

7.  Caveolar peroxynitrite formation impairs endothelial TRPV4 channels and elevates pulmonary arterial pressure in pulmonary hypertension.

Authors:  Zdravka Daneva; Corina Marziano; Matteo Ottolini; Yen-Lin Chen; Thomas M Baker; Maniselvan Kuppusamy; Aimee Zhang; Huy Q Ta; Claire E Reagan; Andrew D Mihalek; Ramesh B Kasetti; Yuanjun Shen; Brant E Isakson; Richard D Minshall; Gulab S Zode; Elena A Goncharova; Victor E Laubach; Swapnil K Sonkusare
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-27       Impact factor: 11.205

8.  Hypoxia-induced Pulmonary Hypertension in Different Mouse Strains: Relation to Transcriptome.

Authors:  Kahori T Ikeda; Philip T Hale; Michael W Pauciulo; Nupur Dasgupta; Patricia A Pastura; Timothy D Le Cras; Manoj K Pandey; William C Nichols
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

9.  Therapeutic Potential of the Nitrite-Generated NO Pathway in Vascular Dysfunction.

Authors:  Michael Madigan; Brian Zuckerbraun
Journal:  Front Immunol       Date:  2013-07-02       Impact factor: 7.561

10.  A novel inhibitor of inducible nitric oxide synthase, ONO-1714, does not ameliorate hypoxia-induced pulmonary hypertension in rats.

Authors:  Bao Hua Jiang; Junko Maruyama; Ayumu Yokochi; Yoshihide Mitani; Kazuo Maruyama
Journal:  Lung       Date:  2007-08-25       Impact factor: 3.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.